Who
Jason David Hanson
Director
Company insider
Files Form 4 as: Director, Bullfrog AI Holdings; Chief Executive Officer, enGene Therapeutics; EVP, Company Group Chairman, Bausch Health Companies; EVP,coo, Medicis Pharmaceutical.
In numbers
- Trades disclosed
- 41
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $3.1M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 10 Jul 2006
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | BFRG Bullfrog AI Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BFRG Bullfrog AI Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 25 Sep 2025filed 29 Sep 2025 | BFRG Bullfrog AI Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 22 Aug 2025filed 26 Aug 2025 | BFRG Bullfrog AI HoldingsBiotechnology | SEC FORM 4 Code A | —5,710 at $0.00 | filing |
| 22 Aug 2025filed 26 Aug 2025 | BFRG Bullfrog AI HoldingsBiotechnology | SEC FORM 4 Code A | —2,813 at $0.00 | filing |
| 26 Sep 2024filed 12 Feb 2025 | BFRG Bullfrog AI Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 7 Jul 2023filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —512,826 | filing |
| 16 Apr 2023filed 9 May 2023 | BFRG Bullfrog AI Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 20 Aug 2021filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —524,544 | filing |
| 20 Aug 2021filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,906 | filing |
| 30 Jul 2019filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,939 | filing |
| 9 Jul 2018filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —137,051 | filing |
| 11 Dec 2012filed 13 Dec 2012 | BHC Bausch Health Companiesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —84,500 at $0.00 | filing |
| 11 Dec 2012filed 13 Dec 2012 | BHC Bausch Health Companiesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —36,300 at $0.00 | filing |
| 11 Dec 2012filed 13 Dec 2012 | Medicis Pharmaceutical | SEC FORM 4 Code D | $9.9M225,513 at $44.00 | filing |
| 17 Aug 2012filed 20 Aug 2012 | Medicis Pharmaceutical | SEC FORM 4 Sold | $1.4M43,496 at $33.02 | filing |
| 4 Apr 2012filed 5 Apr 2012 | Medicis Pharmaceutical | SEC FORM 4 Code F | $182K4,753 at $38.23 | filing |
| 7 Mar 2012filed 9 Mar 2012 | Medicis Pharmaceutical | SEC FORM 4 Code F | $99K2,853 at $34.71 | filing |
| 1 Mar 2012filed 5 Mar 2012 | Medicis Pharmaceutical | SEC FORM 4 Code F | $90K2,589 at $34.95 | filing |
| 1 Mar 2012filed 5 Mar 2012 | Medicis Pharmaceutical | SEC FORM 4 Code F | $51K1,469 at $34.95 | filing |
News
No headline names them, or the companies they trade most, lately.